NCT04780893WithdrawnNot Applicable
A Randomized, Double Blind Sham Controlled, Pilot Study to Evaluate the Efficacy of Vestibular Nerve Stimulation (VeNS) for Sleep Management in People With Post- Traumatic Stress Disorder (PTSD).
Neurovalens Ltd.0 sitesStarted: February 1, 2022Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Withdrawn
- Sponsor
- Primary Endpoint
- Insomnia Severity Index (ISI) score
Study Overview
Brief Summary
This double blind randomized controlled study will enroll 20 subjects and will be conducted remotely. The study will be randomized for an 8-week period with a 1:1 active to sham device allocation. Primary endpoint analysis will be performed at 4 weeks.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Supportive Care
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Signed informed consent
- •Diagnosed PTSD by a medical practitioner
- •Post-Traumatic Checklist (PCL-5) score of 31 or above
- •Insomnia Severity Index (ISI) score of 15 or above
- •Male or female, age ≥ 18 years and ≤ 80 years at the time of signing informed consent
- •Ability and willingness to complete all study visits and procedures, including completion of mental health questionnaires
- •Ability and willingness to adhere to 30 minutes usage of the device daily for the duration of the study
- •No change to PTSD, mental health or insomnia medication within the past 3 months (regimen should be stable)
- •Agreement not to change usage of prescription or over the counter PTSD, mental health or insomnia medications for the duration of the study
- •Agreement not to undergo any significant lifestyle changes that may affect sleep (e.g., excessive exercise, sleep interventions etc.) for the duration of the study
- •Agreement not to use sleep trackers (e.g., Fitbit) for the duration of the study
- •Agreement not to travel across different time zones for the duration of the study
- •Access to Wi-Fi (to enable the study app to upload usage data)
- •Access to computer, laptop, iPad or tablet (to conduct remote study visits and complete study questionnaires remotely)
- •Willing to download and use Zoom (to conduct remote study visits)
Exclusion Criteria
- •History of skin breakdown, eczema, or other dermatological condition (e.g., psoriasis) affecting the skin behind the ears
- •Previous diagnosis of HIV infection or AIDS (HIV is known to cause vestibular neuropathy which would prevent VeNS from working)
- •Use of beta-blockers within 1 month of starting the study
- •A history of stroke or severe head injury as defined by a head injury that required a craniotomy or endotracheal intubation (in case this damaged the neurological pathways involved in vestibular stimulation)
- •Presence of permanently implanted battery powered medical device or stimulator (e.g., pacemaker, implanted defibrillator, deep brain stimulator, vagal nerve stimulator etc.)
- •Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using an adequate contraceptive method
- •Diagnosis of epilepsy
- •Diagnosis of active migraines
- •Previous use of Modius device
- •Participation in other research studies sponsored by Neurovalens
- •Participation in any other sleep or PTSD studies
- •Not fluent in English language
- •Have a member of the same household who is currently participating in this study
- •Failure to agree to use of device daily during study participation
- •History of vestibular dysfunction or other inner ear disease
- •Any other medical condition, or medication use, that in the opinion of the PI is likely to make the subject refractory to VeNS.
Outcomes
Primary Outcomes
Insomnia Severity Index (ISI) score
Time Frame: 4 weeks
To evaluate the effect of the Modius Sleep device, relative to control group on participants with insomnia. ISI is a self-report rating scale assessing the severity of insomnia symptoms (range 0-28) with higher scores indicating a more severe insomnia.
Secondary Outcomes
- PCL-5 Score(4 weeks)
- SF-36 Score(4 weeks)
- Generalised Anxiety Disorder (GAD-7) Scores(4 weeks)
- Prescription reduction(4 weeks)
Investigators
Similar Trials
Completed
Phase 1
Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic PatientsFood AllergyNCT02643862Stanford University48
Completed
Phase 1
A Study to Examine the Pharmacodynamic Effects of GSK1034702 on Neurophysiological Biomarkers of Cognition in Nicotine Abstained Otherwise Healthy SmokersMental DisordersNCT01371799GlaxoSmithKline9
Unknown
Not Applicable
A Randomized, Double-blind, Controlled Study to Evaluate the Safety and Feasibility of a Intraoral Electrotherapy DevicePeriodontal DiseasesNCT04793048Shanghai Keku Medical Technology Co., Ltd.30
Completed
Not Applicable
A Randomized, Double-blind, Sham-controlled Pilot Study to Evaluate the Treatment Efficacy of Magnetic EEG/ECG-Guided Resonance Therapy (MeRT) in College Students With ADHDADHDNCT03066505Wave Neuroscience31
Completed
Not Applicable
The Intervention of Psychobiotics in Patients With Anxiety DisordersAnxiety DisordersNCT05964231Mackay Memorial Hospital71